Following reporting of results for the ELPIS II Phase 2b clinical trial, the Company has requested a meeting with the FDA to review the results to determine potential next steps for the HLHS development program The Company has initiated a process to review all strategic options with a goal of maximizing stockholder value and has implemented cash conservation measures to optimize cost containment Lucid Capital Markets retained as the Company's financial advisor to explore potential strategic opportunities, including a potential business combination MIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial results for the quarter ended September 30, 2026 and provided a business update. “With ELPIS II results now available, we have requested a meeting with the FDA to determine potential next steps for the HLHS development program,” said Stephen H.
